파이프라인
ABL001
Home파이프라인ABL001
Publications
Lee D et al. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. MAbs. 2016 Jul;8(5):892-904.
Choi WH et al. Development, validation, and application of ELISA for detection of anti-HD105 antibodies in pre-clinical safety evaluation using monkeys. J Pharm Biomed Anal. 2016 Nov 30;131:309-315.
Lee J et al. Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer. ASCO 2019
You WK et al. Summary of Phase 1a Dose Escalation Clinical Study Data for Dual Angiogenic Bispecific Antibody Targeting VEGF and DLL4 (ABL001/NOV1501/TR009) in Patients with Previously Treated Solid Tumors. Peptalk 2020
듀얼 VEGF/DLL4 억제를 통한 VEGF 치료제 내성 극복
VEGF와 DLL4의 듀얼억제를 통한 VEGF 내성 극복
- VEGF/DLL 4
- Anti-DLL4와 Anti-VEGF에 비하여 종양크기가 현저히 감소.
Avastin보다 뛰어난 ABL001
ABL001의 잠재적 성공
ABL001 : 국내 최초 이중항체 임상시험
ABL001 : 차세대 최고의 ('베스트인클래스') 이중항체 (BsAb)
